Oversubscribed new share issue prior to listing

The listing on Spotlight Stock Market has been preceded by a new share issue that provided STENOCARE approx.
DKK 18.6 million before issue costs. The new share issue was subscribed to approx. DKK 402 million including subscription commitments of approx. DKK 11.2 million, corresponding to a total subscription ratio of approx. 2,161 percent, and a subscription ratio of the public part of the share issue, i.e. the part that was not pre-subscribed, of approx. 5,281 percent. A total of 11,812 individuals subscribed for shares in the new share issue and STENOCARE received approx. 2,100 new shareholders.  

In addition to operational costs, the proceeds from the issue will finance the development of a production facility for the cultivation and production of medical cannabis.

Financial advisor

Sedermera Fondkommission was the financial advisor and issuing agency to STENOCARE in connection with the new share issue and the listing on Spotlight Stock Market. Nordnet Bank AB was the Selling Agent in the new share issue and Gemstone Capital has assisted the company with marketing in Denmark, etc.

For additional information regarding the new share issue and listing, please contact:

Sedermera Fondkommission

Phone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO

through Press-coordinator Lisbeth Grænge Hansen

Phone: +45 30161097

E-mail: presse@stenocare.com

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot programme. The company was first to receive the Danish Medicines Agency"s permission to import, distribute as well as cultivate and produce medical cannabis. The company offers high quality pharmaceutical grade medical cannabis oil, which is produced by hygienic and high technology cultivation and processing without the use of pesticides. STENOCARE will also develop a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.